tetano
Editor, Senior Moderator
Nat Commun
. 2025 Jul 1;16(1):5592.
doi: 10.1038/s41467-025-59909-6. Cost-effectiveness of the ReDIRECT/counterweight-plus weight management programme to alleviate symptoms of long COVID
Heather L Fraser[SUP] 1 [/SUP], Laura Haag[SUP] 2 [/SUP], Naomi Brosnahan[SUP] 2 3 [/SUP], Alex McConnachie[SUP] 4 [/SUP], Janice Richardson[SUP] 5 [/SUP], Caroline E Haig[SUP] 4 [/SUP], Tracy Ibbotson[SUP] 6 [/SUP], Jane Ormerod[SUP] 7 [/SUP], Catherine A O'Donnell[SUP] 6 [/SUP], Michael E J Lean[SUP] 2 [/SUP], Naveed Sattar[SUP] 5 [/SUP], David N Blane[SUP] 6 [/SUP], Emilie Combet[SUP] 2 [/SUP], Emma McIntosh[SUP] 8 [/SUP]
Affiliations
Long-term effects of COVID-19 infection, termed Long COVID (LC), are associated with reduced quality of life. Symptoms associated with overweight/obesity overlap with and may aggravate those of LC. This paper reports the economic evaluation alongside the ReDIRECT Trial, which evaluated the impact of an evidence-based, remotely-delivered weight management programme on self-reported symptoms of LC in those living with overweight/obesity in the United Kingdom. Recruited participants (n = 234) were randomly allocated to the intervention group (weight management) or control group (usual care). Incremental costs and Quality-Adjusted Life Years (QALYs) were calculated using intervention cost, healthcare resource use and EQ-5D-5L data collected at baseline, three and 6 months. In this work, we show that the ReDIRECT intervention is likely cost-effective in improving LC symptoms from an NHS/PSS perspective, compared to usual care (Incremental Cost-Effectiveness Ratio of £14,754/QALY). Adopting a broader societal perspective, the intervention becomes potentially cost saving compared to usual care.
. 2025 Jul 1;16(1):5592.
doi: 10.1038/s41467-025-59909-6. Cost-effectiveness of the ReDIRECT/counterweight-plus weight management programme to alleviate symptoms of long COVID
Heather L Fraser[SUP] 1 [/SUP], Laura Haag[SUP] 2 [/SUP], Naomi Brosnahan[SUP] 2 3 [/SUP], Alex McConnachie[SUP] 4 [/SUP], Janice Richardson[SUP] 5 [/SUP], Caroline E Haig[SUP] 4 [/SUP], Tracy Ibbotson[SUP] 6 [/SUP], Jane Ormerod[SUP] 7 [/SUP], Catherine A O'Donnell[SUP] 6 [/SUP], Michael E J Lean[SUP] 2 [/SUP], Naveed Sattar[SUP] 5 [/SUP], David N Blane[SUP] 6 [/SUP], Emilie Combet[SUP] 2 [/SUP], Emma McIntosh[SUP] 8 [/SUP]
Affiliations
- PMID: 40593486
- PMCID: PMC12218384
- DOI: 10.1038/s41467-025-59909-6
Long-term effects of COVID-19 infection, termed Long COVID (LC), are associated with reduced quality of life. Symptoms associated with overweight/obesity overlap with and may aggravate those of LC. This paper reports the economic evaluation alongside the ReDIRECT Trial, which evaluated the impact of an evidence-based, remotely-delivered weight management programme on self-reported symptoms of LC in those living with overweight/obesity in the United Kingdom. Recruited participants (n = 234) were randomly allocated to the intervention group (weight management) or control group (usual care). Incremental costs and Quality-Adjusted Life Years (QALYs) were calculated using intervention cost, healthcare resource use and EQ-5D-5L data collected at baseline, three and 6 months. In this work, we show that the ReDIRECT intervention is likely cost-effective in improving LC symptoms from an NHS/PSS perspective, compared to usual care (Incremental Cost-Effectiveness Ratio of £14,754/QALY). Adopting a broader societal perspective, the intervention becomes potentially cost saving compared to usual care.